Selective cardiac plasma-membrane KATP channel inhibition is defibrillatory and improves survival during acute myocardial ischemia and reperfusion

Szilvia Vajda, I. Baczkó, I. Leprán

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

ATP-dependent potassium channels (KATP) have been implicated in cardioprotection both during myocardial ischemia and reperfusion. We compared the effect of a non-selective KATP inhibitor glibenclamide, a selective mitochondrial KATP inhibitor 5-hydroxy-decanoate (5-HD) and a selective sarcolemmal KATP blocker HMR 1883, on survival and incidence of arrhythmias during myocardial ischemia in conscious, and during ischemia-reperfusion in pentobarbitone anesthetized rats. Glibenclamide (5 mg/kg i.p.) or HMR 1883 (3 mg/kg i.v.) reduced ischemia-induced irreversible ventricular fibrillation and improved survival during myocardial ischemia (64% and 61% vs. 23% in controls, respectively). 5-HD (5 mg/kg i.v.) did not influence survival and the incidence of ventricular arrhythmias. The incidence of reperfusion-induced arrhythmias was reduced by both glibenclamide and HMR 1883 (3 or 10 mg/kg) resulting in improved survival during reperfusion (81%, 82% and 96% vs. 24% in controls, respectively) in anesthetized rats. 5-HD did not reduce the incidence of lethal reperfusion arrhythmias. Glibenclamide and HMR 1883 prolonged (89 ± 4.6 and 89 ± 4.9 ms vs. 60 ± 2.4 ms in controls), while 5-HD did not change the QT interval. In conclusion, inhibition of sarcolemmal KATP reduces the incidence of lethal ventricular arrhythmias and improves survival both during acute myocardial ischemia and reperfusion in rats. This beneficial effect correlates with the prolongation of repolarization. Inhibition of mitochondrial KATP does not improve survival or reduce the occurrence of ischemia and/or reperfusion-induced arrhythmias and does not prolong the QT interval. The present results also suggest that the antiarrhythmic effect of KATP inhibitors is not influenced by pentobarbitone anesthesia.

Original languageEnglish
Pages (from-to)115-123
Number of pages9
JournalEuropean Journal of Pharmacology
Volume577
Issue number1-3
DOIs
Publication statusPublished - Dec 22 2007

Fingerprint

KATP Channels
Myocardial Reperfusion
Ion Channels
Decanoates
Myocardial Ischemia
Cardiac Arrhythmias
Glyburide
Reperfusion
Cell Membrane
Incidence
Ischemia
Pentobarbital
Potassium Channels
Ventricular Fibrillation
Anesthesia
Adenosine Triphosphate
clamikalant

Keywords

  • 5-hydroxy-decanoate
  • Glibenclamide
  • HMR 1883
  • Sarcolemmal K channels
  • Ventricular arrhythmias

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

@article{8a04b8cf18474b8a82edb58be1954c06,
title = "Selective cardiac plasma-membrane KATP channel inhibition is defibrillatory and improves survival during acute myocardial ischemia and reperfusion",
abstract = "ATP-dependent potassium channels (KATP) have been implicated in cardioprotection both during myocardial ischemia and reperfusion. We compared the effect of a non-selective KATP inhibitor glibenclamide, a selective mitochondrial KATP inhibitor 5-hydroxy-decanoate (5-HD) and a selective sarcolemmal KATP blocker HMR 1883, on survival and incidence of arrhythmias during myocardial ischemia in conscious, and during ischemia-reperfusion in pentobarbitone anesthetized rats. Glibenclamide (5 mg/kg i.p.) or HMR 1883 (3 mg/kg i.v.) reduced ischemia-induced irreversible ventricular fibrillation and improved survival during myocardial ischemia (64{\%} and 61{\%} vs. 23{\%} in controls, respectively). 5-HD (5 mg/kg i.v.) did not influence survival and the incidence of ventricular arrhythmias. The incidence of reperfusion-induced arrhythmias was reduced by both glibenclamide and HMR 1883 (3 or 10 mg/kg) resulting in improved survival during reperfusion (81{\%}, 82{\%} and 96{\%} vs. 24{\%} in controls, respectively) in anesthetized rats. 5-HD did not reduce the incidence of lethal reperfusion arrhythmias. Glibenclamide and HMR 1883 prolonged (89 ± 4.6 and 89 ± 4.9 ms vs. 60 ± 2.4 ms in controls), while 5-HD did not change the QT interval. In conclusion, inhibition of sarcolemmal KATP reduces the incidence of lethal ventricular arrhythmias and improves survival both during acute myocardial ischemia and reperfusion in rats. This beneficial effect correlates with the prolongation of repolarization. Inhibition of mitochondrial KATP does not improve survival or reduce the occurrence of ischemia and/or reperfusion-induced arrhythmias and does not prolong the QT interval. The present results also suggest that the antiarrhythmic effect of KATP inhibitors is not influenced by pentobarbitone anesthesia.",
keywords = "5-hydroxy-decanoate, Glibenclamide, HMR 1883, Sarcolemmal K channels, Ventricular arrhythmias",
author = "Szilvia Vajda and I. Baczk{\'o} and I. Lepr{\'a}n",
year = "2007",
month = "12",
day = "22",
doi = "10.1016/j.ejphar.2007.08.016",
language = "English",
volume = "577",
pages = "115--123",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Selective cardiac plasma-membrane KATP channel inhibition is defibrillatory and improves survival during acute myocardial ischemia and reperfusion

AU - Vajda, Szilvia

AU - Baczkó, I.

AU - Leprán, I.

PY - 2007/12/22

Y1 - 2007/12/22

N2 - ATP-dependent potassium channels (KATP) have been implicated in cardioprotection both during myocardial ischemia and reperfusion. We compared the effect of a non-selective KATP inhibitor glibenclamide, a selective mitochondrial KATP inhibitor 5-hydroxy-decanoate (5-HD) and a selective sarcolemmal KATP blocker HMR 1883, on survival and incidence of arrhythmias during myocardial ischemia in conscious, and during ischemia-reperfusion in pentobarbitone anesthetized rats. Glibenclamide (5 mg/kg i.p.) or HMR 1883 (3 mg/kg i.v.) reduced ischemia-induced irreversible ventricular fibrillation and improved survival during myocardial ischemia (64% and 61% vs. 23% in controls, respectively). 5-HD (5 mg/kg i.v.) did not influence survival and the incidence of ventricular arrhythmias. The incidence of reperfusion-induced arrhythmias was reduced by both glibenclamide and HMR 1883 (3 or 10 mg/kg) resulting in improved survival during reperfusion (81%, 82% and 96% vs. 24% in controls, respectively) in anesthetized rats. 5-HD did not reduce the incidence of lethal reperfusion arrhythmias. Glibenclamide and HMR 1883 prolonged (89 ± 4.6 and 89 ± 4.9 ms vs. 60 ± 2.4 ms in controls), while 5-HD did not change the QT interval. In conclusion, inhibition of sarcolemmal KATP reduces the incidence of lethal ventricular arrhythmias and improves survival both during acute myocardial ischemia and reperfusion in rats. This beneficial effect correlates with the prolongation of repolarization. Inhibition of mitochondrial KATP does not improve survival or reduce the occurrence of ischemia and/or reperfusion-induced arrhythmias and does not prolong the QT interval. The present results also suggest that the antiarrhythmic effect of KATP inhibitors is not influenced by pentobarbitone anesthesia.

AB - ATP-dependent potassium channels (KATP) have been implicated in cardioprotection both during myocardial ischemia and reperfusion. We compared the effect of a non-selective KATP inhibitor glibenclamide, a selective mitochondrial KATP inhibitor 5-hydroxy-decanoate (5-HD) and a selective sarcolemmal KATP blocker HMR 1883, on survival and incidence of arrhythmias during myocardial ischemia in conscious, and during ischemia-reperfusion in pentobarbitone anesthetized rats. Glibenclamide (5 mg/kg i.p.) or HMR 1883 (3 mg/kg i.v.) reduced ischemia-induced irreversible ventricular fibrillation and improved survival during myocardial ischemia (64% and 61% vs. 23% in controls, respectively). 5-HD (5 mg/kg i.v.) did not influence survival and the incidence of ventricular arrhythmias. The incidence of reperfusion-induced arrhythmias was reduced by both glibenclamide and HMR 1883 (3 or 10 mg/kg) resulting in improved survival during reperfusion (81%, 82% and 96% vs. 24% in controls, respectively) in anesthetized rats. 5-HD did not reduce the incidence of lethal reperfusion arrhythmias. Glibenclamide and HMR 1883 prolonged (89 ± 4.6 and 89 ± 4.9 ms vs. 60 ± 2.4 ms in controls), while 5-HD did not change the QT interval. In conclusion, inhibition of sarcolemmal KATP reduces the incidence of lethal ventricular arrhythmias and improves survival both during acute myocardial ischemia and reperfusion in rats. This beneficial effect correlates with the prolongation of repolarization. Inhibition of mitochondrial KATP does not improve survival or reduce the occurrence of ischemia and/or reperfusion-induced arrhythmias and does not prolong the QT interval. The present results also suggest that the antiarrhythmic effect of KATP inhibitors is not influenced by pentobarbitone anesthesia.

KW - 5-hydroxy-decanoate

KW - Glibenclamide

KW - HMR 1883

KW - Sarcolemmal K channels

KW - Ventricular arrhythmias

UR - http://www.scopus.com/inward/record.url?scp=35449004964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35449004964&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2007.08.016

DO - 10.1016/j.ejphar.2007.08.016

M3 - Article

C2 - 17904545

AN - SCOPUS:35449004964

VL - 577

SP - 115

EP - 123

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -